What is Epizyme Scaled Net Operating Assets?
Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.
Epizyme's operating assets for the quarter that ended in Jun. 2022 was $119.75 Mil. Epizyme's operating liabilities for the quarter that ended in Jun. 2022 was $46.73 Mil. Epizyme's Total Assets for the quarter that ended in Mar. 2022 was $312.19 Mil. Therefore, Epizyme's scaled net operating assets (SNOA) for the quarter that ended in Jun. 2022 was 0.23.
Epizyme Scaled Net Operating Assets Historical Data
The historical data trend for Epizyme's Scaled Net Operating Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Epizyme Scaled Net Operating Assets Chart
|
Epizyme Annual Data
|
|
Trend |
Dec12 |
Dec13 |
Dec14 |
Dec15 |
Dec16 |
Dec17 |
Dec18 |
Dec19 |
Dec20 |
Dec21 |
| Scaled Net Operating Assets |
|
Get a 7-Day Free Trial
|
|
|
-0.16 |
-0.03 |
-0.02 |
0.11 |
0.09 |
|
Epizyme Quarterly Data
|
|
Sep17 |
Dec17 |
Mar18 |
Jun18 |
Sep18 |
Dec18 |
Mar19 |
Jun19 |
Sep19 |
Dec19 |
Mar20 |
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
Jun22 |
| Scaled Net Operating Assets |
Get a 7-Day Free Trial
|
|
|
|
|
|
|
|
|
|
|
|
|
0.14 |
0.10 |
0.13 |
0.17 |
0.23 |
Competitive Comparison of Epizyme's Scaled Net Operating Assets
For the Biotechnology subindustry, Epizyme's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Epizyme's Scaled Net Operating Assets Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Epizyme's Scaled Net Operating Assets distribution charts can be found below:
* The bar in red indicates where Epizyme's Scaled Net Operating Assets falls into.
Epizyme Scaled Net Operating Assets Calculation
Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.
Epizyme's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2021 is calculated as
| Scaled Net Operating Assets (SNOA) | | (A: Dec. 2021 ) |
| = | (Operating Assets (A: Dec. 2021 ) | - | Operating Liabilities (A: Dec. 2021 )) | / | Total Assets (A: Dec. 2020 ) |
| = | (112.21 | - | 70.576) | / | 473.573 |
| = | 0.09 |
where
Epizyme's Scaled Net Operating Assets (SNOA) for the quarter that ended in Jun. 2022 is calculated as
| Scaled Net Operating Assets (SNOA) | | (Q: Jun. 2022 ) |
| = | (Operating Assets (Q: Jun. 2022 ) | - | Operating Liabilities (Q: Jun. 2022 )) | / | Total Assets (Q: Mar. 2022 ) |
| = | (119.747 | - | 46.727) | / | 312.186 |
| = | 0.23 |
where
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Epizyme (Epizyme) Business Description
Traded in Other Exchanges
N/A
Address
400 Technology Square, 4th Floor, Cambridge, MA, USA, 02139
Epizyme Inc is a clinical-stage biopharmaceutical company that is committed to rewriting treatment for cancer and other serious diseases through discovering, developing, and commercializing novel epigenetic medicines. Its product candidates include one approved product, TAZVERIK (tazemetostat), an inhibitor of the EZH2. The company is also developing additional programs, such as pinometostat, an intravenously administered small molecule inhibitor of DOT1L for the treatment of acute leukemias and PRMT5 inhibitor.
Executives
| Jeffery Kutok |
officer: Chief Scientific Officer |
784 MEMORIAL DRIVE, CAMBRIDGE MA 02139 |
| Jerald Korn |
officer: Chief Operating Officer |
128 GORDON RD, NEWTON MA 02468 |
| Joseph Beaulieu |
officer: Corporate Controller |
C/O EPIZYME, INC. 400 TECHNOLOGY SQUARE CAMBRIDGE MA 02139 |
| Shefali Agarwal |
officer: Chief Medical Officer |
C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139 |
| Royalty Pharma Investments 2019 Icav |
director, 10 percent owner |
C/O RP MANAGEMENT, LLC 100 E. 59TH ST., 33RD FLOOR NEW YORK NY 10022 |
| Pablo G. Legorreta |
director |
110 E 59TH STREET, SUITE 3300, NEW YORK NY 10022 |
| Carol Stuckley |
director |
C/O CENTESSA PHARMACEUTICALS PLC, 3RD FLOOR, 1 ASHLEY ROAD, ALTRINCHAM, CHESHIRE X0 WA14 2DT |
| Roy A Beveridge, |
director |
500 W MAIN ST, LOUISVILLE KY 40202 |
| David M Mott |
director |
1119 ST. PAUL STREET, BALTIMORE MD 21202 |
| Robert B Bazemore |
director, officer: President & CEO |
33 HAYDEN AVE, LEXINGTON MA 02421 |
| Matthew Ros |
officer: Chief Operating Officer |
C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139 |
| Paolo Tombesi |
officer: Chief Financial Officer |
10 FINDERNE AVENUE, BUILDING 10, BRIDGEWATER NJ 08807 |
| Victoria Vakiener |
officer: Chief Commercial Officer |
C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139 |
| Carl Goldfischer |
director |
161 WEST 61ST STREET, NEW YORK NY 10022 |
| Rp Management, Llc |
director |
110 EAST 59TH STREET SUITE 3300 NEW YORK NY 10022 |
Epizyme (Epizyme) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
EPZM has been successfully added to your